PARP1 and neoplasm: A recent study by Liberman’s team23 has shown that NMD inhibition with an Upf2 AsiC in combination with Parp1, Mcl1, and CD47 tumor target inhibition leads to disease control in Balb neut Erb2ΔEx16 mice.